Lisata Therapeutics
LSTA
24 hedge funds and large institutions have $2.5M invested in Lisata Therapeutics in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 6 closing their positions.
126% more capital invested
Capital invested by funds: $1.11M → $2.5M (+$1.4M)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0.08% more ownership
Funds ownership: 0.32% → 0.4% (+0.08%)
20% less funds holding
Funds holding: 30 → 24 (-6)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$288K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$197K |
| 3 |
BlackRock
New York
|
+$123K |
| 4 |
Renaissance Technologies
New York
|
+$115K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$71.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$45K |
| 2 |
Goldman Sachs
New York
|
-$31K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$31K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$13.4K |
| 5 |
Morgan Stanley
New York
|
-$8.38K |
LSTA Hedge Fund Activity: Q1 2017 in Review
24 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2017, worth a combined $2.5M — up 126% from $1.11M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LSTA and 2 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Knoll Capital Management, adding an estimated $288K. The largest seller was Citadel Advisors, exiting entirely with an estimated $45K sold.
- 24 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2017, down from 30 in Q4 2016.
- Funds reported $2.5M of Lisata Therapeutics stock for Q1 2017, up 126% quarter-over-quarter.
- 2 funds opened new Lisata Therapeutics positions in Q1 2017 and 6 closed out, a net change of -4 holders.
- The largest Lisata Therapeutics buyer in Q1 2017 was Knoll Capital Management, an estimated $288K added.
- The largest Lisata Therapeutics seller in Q1 2017 was Citadel Advisors, an estimated $45K sold.
Based on aggregated 13F filings for Q1 2017.